

Immunoscore[®], Immunosign[®] and Halioseek[®] at SITC 2017

- HalioDx immune scoring solutions results presented by our biopharma partners at SITC 2017
- Halioseek[®] PD-L1/CD8 potential to improve selection of NSCLC¹ patients eligible to ICI²
- Meet HalioDx team at booth #512 to discuss abstracts content, discover HalioDx products and services

Marseille, France, November 8th, 2017 – HalioDx SAS, an immuno-oncology diagnostic company, announced its participation at the SITC 2017 Annual Meeting with several posters presented by its collaborators and partners.

HalioDx will also present a poster on its Halioseek[®] PD-L1/CD8³ assay which is now CE-IVD in Europe since October ([See press release on Halioseek[®] CE-IVD launch](#)).

HalioDx team will showcase its diagnostic products including Immunoscore[®] Colon and clinical research services on booth #512 and will be pleased to discuss with attendees during the SITC conference.

Vincent FERT, CEO of HalioDx comments: *“SITC 2017 meeting is a unique opportunity for HalioDx to showcase the value of our Clinical Research portfolio through data presented by our biopharmaceutical partners, and to update attendees on our progresses toward establishing our immune scoring solutions as standards in immunotherapies clinical development.”*

Poster presentations by our partners:

‘Antitumor immunity in patients with locally advanced soft tissue sarcoma treated with hafnium oxide nanoparticles and radiation therapy’

Poster Session: Oncolytic Viruses and Intratumoral Therapies

Poster Board #412

Session Time: Saturday, November 11, 2017 - 12:30 to 2 p.m. and 6:30 to 8 p.m.

Presenter: Sebastien Paris, Nanobiotix, Paris, France

‘LTX-315, a first in class oncolytic peptide, reshapes the tumor microenvironment in the majority of patients with advanced metastatic tumors: Results from an ongoing study’

Poster Session: Clinical Trials (In Progress)

Poster Board #250

Session Time: Saturday, November 11, 2017 - 12:30 to 2 p.m. and 6:30 to 8 p.m.

Presenter: Aurelien Marabelle, Gustave Roussy, Villejuif, France

¹ Non-Small Cell Lung Cancer.

² Immune Checkpoint Inhibitors.

³ For Research Use Only in USA. Not for Use in Diagnostic Procedures.

Poster presentation by HalioDx:

'Halioseek[®], a dual CD8 and PD-L1 IVD assay to improve NSCLC patients stratification'

Poster Session: Biomarkers and Immune Monitoring

Poster Board #70

Session Time: Saturday, November 11, 2017 - 12:30 to 2 p.m. and 6:30 to 8 p.m.

Presenter: Jacques Fieschi, HalioDx, Marseille, France

About HalioDx

The Immune Response to Cancer Diagnostics

HalioDx is an immuno-oncology diagnostic company providing oncologists with first-in-class Immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.

Immunoscore[®] proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with advanced imaging analysis enabling extraction of spatially-organized tissue molecular information. Immunoscore[®] is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. HalioDx collaborates with renowned international clinical groups to support clinical utility and ensure rigorous performance validation of its assays in selected cancer indications. HalioDx develops also assays such as Halioseek[®] and Immunosign[®] to help stratifying patients for immunotherapies.

HalioDx has an experienced team of more than 130 employees, a CLIA laboratory and compliant facilities to develop, manufacture, register and market *in vitro* diagnostic (IVD) products and perform patient sample testing in a GCP/GCLP compliant environment. HalioDx executes biomarker studies and companion diagnostic assay development in conformity with regulations and in partnership with biopharmaceutical companies. The company co-founded the European immunology cluster Marseille Immunopôle (MI).

For more information, please visit our websites www.halioldx.com, www.immunoscore-colon.com and www.halioseek.com and follow the company on Twitter [@HalioDx](https://twitter.com/HalioDx).

Contacts

HalioDx SAS**Vincent Fert**

President and CEO

+ 33 (0)4 91 29 30 90

vincent.fert@haliodx.com

ATCG Press

Marie Puvieux (France)

Mob: +33 (0)6 10 54 36 72

Jean-Mehdi Grangeon (ROW)

Mob: +33 (0)6 62 22 00 24

haliodx@atcg-partners.com